The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, and regulatory challenges you’ll face as you navigate your company from an idea to success in the clinic. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is p ...
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up for Busy Scientists
David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado
The Go-to Podcast for Biotech Scientists Who Want to Master Bioprocess CMC Development and Manufacturing of Biologics. **TOP 10 LIFE SCIENCES PODCAST** Do you want to simplify bioprocessing so that you can scale with confidence and reduce time to market? Are you sick of feeling overwhelmed by the complexity and guesswork of biologics drug development? Do you wish you had more time to enjoy the beauty of science, without worrying about failing your cell culture process development and commerc ...
…
continue reading
![Artwork](/static/images/128pixel.png)
1
72: Effective Outsourcing: How Small Biotech Companies Can Thrive w/ Mark Melville - Part 2
21:59
21:59
Play later
Play later
Lists
Like
Liked
21:59
How do small biotech companies make strategic decisions with limited resources? This episode dives deep into the art of prioritization and outsourcing to achieve success. Join us as we speak with Mark Melville, Vice President of CMC, Biologics at Cullinan Therapeutics, a seasoned biotech scientist with years of experience in both large and small bi…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
71: Effective Outsourcing: How Small Biotech Companies Can Thrive w/ Mark Melville - Part 1
18:32
18:32
Play later
Play later
Lists
Like
Liked
18:32
Are you navigating the complex world of bioprocess CMC development and manufacturing in a small biotech company? Our latest episode is a must-listen! Join us as we sit down with Mark Melville, Vice President of CMC, Biologics at Cullinan Therapeutics, who shares invaluable insights on overcoming the unique challenges faced by small biotech firms. I…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
First AI Antibody In Humans with Aulos' Aron Knickerbocker
1:08:52
1:08:52
Play later
Play later
Lists
Like
Liked
1:08:52
We love to hear from our listeners. Send us a message. Data drives decision-making at Aulos Bioscience. It's also driven the career trajectory of its CEO. On this week's episode of the Business of Biotech podcast, we get an introspective walk through Aron Kinickerbocker's strategically-orchestrated career path, from his early days in the labs at Br…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
70: Glycoanalytics Explained: Analysing and Designing Better Biopharmaceutical Drugs w/ Róisín O’Flaherty - Part 2
15:31
15:31
Play later
Play later
Lists
Like
Liked
15:31
In this insightful episode, we explore the cutting-edge field of glycoengineering and its transformative impact on biopharmaceutical drug design. Join us as we chat with Róisín O’Flaherty, Assistant Professor in the Department of Chemistry at Maynooth University, to uncover the nuances of chemoenzymatic glycogen engineering and its potential to rev…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
69: Glycoanalytics Explained: Analysing and Designing Better Biopharmaceutical Drugs w/ Róisín O’Flaherty - Part 1
18:09
18:09
Play later
Play later
Lists
Like
Liked
18:09
Uncover the hidden science behind creating safer, more effective biological drugs! Dive into glycoanalytics and glycoengineering, the secret weapons revolutionizing biopharma. Join us as we talk with Róisín O’Flaherty, Assistant Professor in the Department of Chemistry at Maynooth University, who breaks down the complexities of glycosylation and it…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Drug Delivery Differentiators with Syncromune's Eamonn Hobbs
1:12:31
1:12:31
Play later
Play later
Lists
Like
Liked
1:12:31
We love to hear from our listeners. Send us a message. Syncromune's Sync-T solid tumor therapeutic platform is, in a word, complex. The company's three phase 1 programs combine T-cell science with a proprietary drug delivery device to target solid tumors, specifically metastatic breast, non-small-cell lung, and castrate-resistant prostate cancers. …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
68: How Process Mapping Transforms Knowledge Management in Biotech w/ Irwin Hirsh - Part 2
28:53
28:53
Play later
Play later
Lists
Like
Liked
28:53
Join us as we explore the pivotal role of process mapping in biotech knowledge management. Our guest, Irwin Hirsh, a seasoned biotech consultant concentrating on enhancing business efficiency and effectiveness, shares invaluable insights into leveraging technology to streamline operations. Key Insights: Identifying Critical Process Knowledge: Learn…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
67: How Process Mapping Transforms Knowledge Management in Biotech w/ Irwin Hirsh - Part 1
14:22
14:22
Play later
Play later
Lists
Like
Liked
14:22
Want to turn your biotech chaos into streamlined success? Learn from expert Irwin Hirsh, a seasoned biotech consultant concentrating on enhancing business efficiency and effectiveness, on how process mapping can transform your knowledge management and elevate your business performance. Key Takeaways: Eliminate Scope Creep: Learn how to maintain foc…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Topical Ocular Biologics with Claris Bio's Clarke Atwell
58:06
58:06
Play later
Play later
Lists
Like
Liked
58:06
We love to hear from our listeners. Send us a message. Built on the back of hepatocyte growth factor discoveries by Harvard Drs. Reza Dana and Sunil Chauhan, ClarisBio is rewriting the ophthalmology rulebook. CEO Clark Atwell acknowledges that it's not the first to bring topically-administered biologic therapies to the front of the eye, but if succ…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
66: Freezing and Thawing Cells: the Science Behind Cryopreservation w/ Mark Davison - Part 2
16:08
16:08
Play later
Play later
Lists
Like
Liked
16:08
Get ready to dive into the fascinating world of cryopreservation! In this episode, we welcome Mark Davison, an experienced entrepreneur and CEO of Grant Instruments, leaders in laboratory equipment, to explore the intricate science of freezing and thawing cells. Mark brings his wealth of experience to demystify this crucial process, revealing how c…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
65: Freezing and Thawing Cells: the Science Behind Cryopreservation w/ Mark Davison - Part 1
24:15
24:15
Play later
Play later
Lists
Like
Liked
24:15
Picture a world where we can freeze cells and bring them back to life perfectly intact. In this episode, we're joined by Mark Davison, a leading expert in cryopreservation and CEO of Grant Instruments to uncover the intricate science of freezing and thawing cells. From basic principles to advanced techniques, we delve into how cryopreservation is r…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
C&G Regulatory Guidance with Lineage Therapeutics' Brian Culley
1:04:02
1:04:02
Play later
Play later
Lists
Like
Liked
1:04:02
We love to hear from our listeners. Send us a message. When we last caught up with Brian Culley, CEO at Lineage Cell Therapeutics, it was January, 2021. A pandemic was raging. His company was moving mountains to keep its OpRegen dry AMD clinical trial together, and did so despite lockdowns that kept a largely aged patient population from setting fo…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
64: Why Sound Waves Are the Future of Gene Therapy Bioreactors w/ Gabriel Dumy - Part 2
21:52
21:52
Play later
Play later
Lists
Like
Liked
21:52
Could sound waves be the revolutionary key to gene therapy manufacturing? In this episode, Gabriel Dumy, CTO and Co-founder at Kolibri, reveals how acoustic waves are set to transform cell harvesting and gene transfection processes, making biomanufacturing more efficient and less damaging to cells. Kolibri is a company revolutionizing the way we gr…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
63: Why Sound Waves Are the Future of Gene Therapy Bioreactors w/ Gabriel Dumy - Part 1
25:27
25:27
Play later
Play later
Lists
Like
Liked
25:27
Are sound waves the key to revolutionizing gene therapy? In this groundbreaking episode, we sit down with Gabriel Dumy, CTO and Co-founder at Kolibri, a company revolutionizing the way we grow and engineer cells at scale using acoustic waves. Gabriel shares the challenges facing modern bioproduction and unveils an exciting solution that's setting t…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
True DEI Value in Biopharma with Arcellx's Rami Elghandour
1:04:08
1:04:08
Play later
Play later
Lists
Like
Liked
1:04:08
We love to hear from our listeners. Send us a message. The cell therapy company Arcellx has, by any and every measure, been outperforming its peers. Its stock has rallied on the back of the strong performance of its multiple myeloma candidate, and the promise of its AML, MDS, and solid tumor pipelines is attracting the kind of interest it takes to …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
62: Magnetic Bead Technology: The New Era in Downstream Processing w/ Nils Brechmann - Part 2
15:16
15:16
Play later
Play later
Lists
Like
Liked
15:16
Dive into the future of bioprocessing with Nils Brechmann, Marketing Manager at MAGic BioProcessing and co-inventor of the process applications, as we explore how magnetic bead technology is transforming downstream processing. MAGic BioProcessing is a biotech company from Uppsala, Sweden, that develops magnetic-based recovery of biologicals. Key Ta…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
61: Magnetic Bead Technology: The New Era in Downstream Processing w/ Nils Brechmann - Part 1
19:22
19:22
Play later
Play later
Lists
Like
Liked
19:22
Dive into the latest episode as we explore how magnetic bead technology is revolutionizing downstream processing, promising higher yields and greater purity. Our guest, Nils Brechmann, Marketing Manager at MAGic BioProcessing and co-inventor of the process applications, shares his insights on overcoming industry challenges and the future of purific…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Mission-Driven Dementia Funding with DDF's Jonathan Behr
55:46
55:46
Play later
Play later
Lists
Like
Liked
55:46
We love to hear from our listeners. Send us a message. If there's anyone qualified to analyze an early-stage therapeutic technology and place bets with other people's money, it's scientist-turned-venture capitalist Jonathan Behr, Ph.D. He built a distinguished venture capital career on the back of an MIT Ph.D. in biological engineering, having co-f…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
60: Next-Generation Sequencing: Transforming Science and Medicine w/ Jonathon Hill - Part 2
20:37
20:37
Play later
Play later
Lists
Like
Liked
20:37
Unlock the future of epigenetics and join us for an insightful conversation with Jonathon Hill as he delves into the groundbreaking world of next-generation sequencing (NGS) and its transformative impact on science and medicine. Jonathon Hill is the VP of Science and Technology and a co-founder of Wasatch BioLabs and Associate Professor of Cell Bio…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
59: Next-Generation Sequencing: Transforming Science and Medicine w/ Jonathon Hill - Part 1
16:46
16:46
Play later
Play later
Lists
Like
Liked
16:46
Curious about the latest advancements in next-generation sequencing (NGS) and how they are revolutionizing science and medicine? In this episode, we delve into the cutting-edge developments of NGS with our expert guest, Jonathon Hill, VP of Science and Technology and a co-founder of Wasatch BioLabs and Associate Professor of Cell Biology and Physio…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
ADCs Ignited with Daiichi Sankyo Inc.'s Ken Keller
1:04:06
1:04:06
Play later
Play later
Lists
Like
Liked
1:04:06
We love to hear from our listeners. Send us a message. Just a few years ago, Daiichi Sankyo wasn't considered a player in the oncology therapeutics space, and it certainly wasn't a player in ADCs. But then, just a few years ago, who was? Fast forward to 2023, and we see an ADC arena that drove nearly $100 billion in M&A, licensing, and partnership …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls w/ Matthias Müllner - Part 2
19:08
19:08
Play later
Play later
Lists
Like
Liked
19:08
Dive into the realm of biotech with our latest episode as we unravel the enigma of Quality by Design (QbD) with Matthias Müllner, CEO of & Co-Founder bespark*bio, a company empowering viral vector-based medicines. Discover how integrating QbD principles early in your development cycle can revolutionize your approach to producing safe, high-quality …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
57: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls w/ Matthias Müllner - Part 1
17:14
17:14
Play later
Play later
Lists
Like
Liked
17:14
Join us for an insightful episode as we dive into the world of bioprocess CMC development strategies with Matthias Müllner, CEO of & Co-Founder bespark*bio, a company empowering viral vector-based medicines. Matthias shares his wealth of knowledge on avoiding common pitfalls in developing robust Chemistry, Manufacturing, and Controls (CMC) strategi…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Accelerating ADCs with Mythic Therapeutics' Brian Fiske, Ph.D.
56:38
56:38
Play later
Play later
Lists
Like
Liked
56:38
We love to hear from our listeners. Send us a message. Mythic Therapeutics Chief Scientific Officer and co-founder Brian Fiske, Ph.D. broke some unwritten protocol with his rapid and multifaceted transition from academia to industry. He calls his many, and sometimes concurrent, early experiences as an MIT Ph.D. student, a Flagship Ventures Fellow, …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
56: Cultivated Meat: A Promising Future or an Inevitable Bubble? w/ Steven Lang - Part 2
15:07
15:07
Play later
Play later
Lists
Like
Liked
15:07
Is cultivated meat the food of tomorrow or just a passing trend? In this episode, we dive deep with Steven Lang, an expert in the field of cultivated meat. Steven sheds light on the intricate process of creating meat in the lab, the challenges faced, and the potential future of this innovative industry. Key Takeaways: Precision in Analytics: Discov…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
55: Cultivated Meat: A Promising Future or an Inevitable Bubble? /w Steven Lang - Part 1
22:45
22:45
Play later
Play later
Lists
Like
Liked
22:45
How can you create an environment suitable for shear-stress-sensitive cells that results in higher cell concentrations and superior quality? Essentially, bionic bioreactors revolutionize this process, changing the game rules with their ability to facilitate bubble-free gas exchange. Join us in this episode as we unravel the groundbreaking innovatio…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
The Anti-CDMO with CTMC's Jason Bock, Ph.D. and KSQ's Thomas Leitch
57:35
57:35
Play later
Play later
Lists
Like
Liked
57:35
We love to hear from our listeners. Send us a message. This isn't your typical drug sponsor + CDMO story. In fact, CTMC's Jason Bock, Ph.D. says you shouldn't even classify his company a CDMO. He's not wrong. While some of the company's services aren't dissimilar from those offered by a contract developer, CTMC began with a more fundamental mission…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
54: Bionic Bioreactors: The Key to Stress-Free Cell Cultivation w/ Patrick Bongartz - Part 2
19:19
19:19
Play later
Play later
Lists
Like
Liked
19:19
How can you create an environment suitable for shear-stress-sensitive cells that results in higher cell concentrations and superior quality? Essentially, bionic bioreactors revolutionize this process, changing the game rules with their ability to facilitate bubble-free gas exchange. Join us in this episode as we unravel the groundbreaking innovatio…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
53: Bionic Bioreactors: The Key to Stress-Free Cell Cultivation w/ Patrick Bongartz - Part 1
18:20
18:20
Play later
Play later
Lists
Like
Liked
18:20
How can you provide stress-free cultivation conditions to achieve higher cell concentrations and quality? In a nutshell, bionic bioreactors and thus change bubble-free gas exchange change the game. Join us as we delve into the future of biotech with our guest, Patrick Bongartz, CEO of BioThrust and an expert in innovative bioreactor design. Key Hig…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
A New Prescription For PBMs with Allan Shaw
40:13
40:13
Play later
Play later
Lists
Like
Liked
40:13
We love to hear from our listeners. Send us a message. Back by popular demand, biopharma industry opinionator extraordinaire Allan Shaw rejoins the Business of Biotech to expose the murky role Pharmacy Benefit Managers (PBMs) play in the last, costly mile of the drug distribution supply chain. Allan pulls no punches in his criticism of the current …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
52: Unraveling the Complexity of Commercializing Cell and Gene Therapies w/ Wajiha Ali - Part 2
25:41
25:41
Play later
Play later
Lists
Like
Liked
25:41
Does the process of commercializing cell and gene therapies seem complex and unclear to you? Dive deep into the groundbreaking world of cell and gene therapies with our guest, Wajiha Ali, a strategy expert who believes in bridging the gap between research and commercialization with data, as we unravel the complexities of bringing life-saving therap…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
51: Unraveling the Complexity of Commercializing Cell and Gene Therapies w/ Wajiha Ali - Part 1
19:26
19:26
Play later
Play later
Lists
Like
Liked
19:26
Are you finding the path to commercializing cell and gene therapies complex and uncertain? Join us as we explore this intricate landscape with our guest, Wajiha Ali. As a strategy expert who believes in bridging the gap between research and commericalization with data who she will guide us through the challenges, victories, and vital strategies for…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
New Apps For AI in mRNA With Anima Biotech's Yochi Slonim
59:10
59:10
Play later
Play later
Lists
Like
Liked
59:10
We love to hear from our listeners. Send us a message. From San Francisco’s Silicon Valley to Tel Aviv’s Silicon Wadi, software business entrepreneur Yochi Slonim made a name for himself in global tech hubs around the globe. Notably, he was co-founder of billion-dollar Mercury Interactive, which HP acquired for $4.5 billion, and previous to that a …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
50: Decode Bioprocess Success: The Art of Stakeholder Management - Part 2
11:08
11:08
Play later
Play later
Lists
Like
Liked
11:08
In the second part of "Decode Bioprocess Success: The Art of Stakeholder Management," we delve deeper into the strategies for effective stakeholder management in bioprocess development. Through a step-by-step approach, we explore how to identify, classify, and engage with stakeholders to ensure project success. Key highlights: Learn how to create a…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
49: Decode Bioprocess Success: The Art of Stakeholder Management - Part 1
17:10
17:10
Play later
Play later
Lists
Like
Liked
17:10
In this episode, we embark on a journey to uncover the essential strategies for navigating stakeholder relationships in bioprocess CMC development projects. We delve into the critical role of stakeholders in bioprocess development and how their engagement can determine the success or failure of a project. Drawing from real-life experiences and insi…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Circular RNA with Orna Therapeutics' Tom Barnes, Ph.D. and Advancing RNA's Anna Rose Welch
59:11
59:11
Play later
Play later
Lists
Like
Liked
59:11
We love to hear from our listeners. Send us a message. As if Orna Therapeutics' CEO Thomas Barnes, CEO isn't a enough to draw you in to the Business of Biotech, we teamed up with Advancing RNA Editorial & Community Director Anna Rose Welch to co-host this week's episode. Together, Anna Rose and I press Dr. Barnes on his transition from academia to …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
48: Mastering Process Economics: Driving Down Costs in Antibody Production w/ Brian Kelley - Part 2
18:54
18:54
Play later
Play later
Lists
Like
Liked
18:54
Unlock the secrets to cost-efficient antibody therapeutics with Brian Kelley, Senior Vice President of Process Development at VIR Biotechnology. In this illuminating episode, industry expert Brian Kelley shares invaluable insights into driving down manufacturing costs while maintaining quality and accessibility. From optimizing batch sizes to maxim…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
47: Mastering Process Economics: Driving Down Costs in Antibody Production w/ Brian Kelley - Part 1
16:55
16:55
Play later
Play later
Lists
Like
Liked
16:55
Join us in this enlightening episode as we explore process economics with industry expert Brian Kelley. He is the Senior Vice President of Process Development at VIR Biotechnology. Unraveling the mysteries of cost management in antibody therapeutics, Brian sheds light on the intricate challenges faced by biotech scientists and engineers. Key Highli…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Physician + Biotech Builder with Tome Biosciences' Rahul Kakkar, M.D.
1:01:30
1:01:30
Play later
Play later
Lists
Like
Liked
1:01:30
We love to hear from our listeners. Send us a message. Novel technologies aren’t interesting to Rahul Kakkar, M.D. unless they help patients. Sounds rational, but it’s actually a unique perspective in a platform-crazed biotech industry. Dr. Kakkar’s worldview is shaped by his work as a physician—work he continues at Brigham and Women’s Hospital eve…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
46: From Lab to Table: The Science Behind Cultivated Meat w/ Petra Hanga - Part 2
25:54
25:54
Play later
Play later
Lists
Like
Liked
25:54
Dive into the future of food with our latest episode, "From Lab to Table: The Science Behind Cultivated Meat." With our guest, Petra Hanga, a Lecturer in Biochemical Engineering at University College London and Chief Scientific Officer of Quest Meat Ltd., we unravel the secrets behind this groundbreaking technology. Key highlights: 1. Discover how …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
45: From Lab to Table: The Science Behind Cultivated Meat w/ Petra Hanga - Part 1
14:26
14:26
Play later
Play later
Lists
Like
Liked
14:26
Dive into the fascinating world of cultivated meat with our guest, Petra Hanga, Lecturer in Biochemical Engineering – Cellular Agriculture at University College London and the Chief Scientific Officer of Quest Meat Ltd. In this episode, Petra sheds light on the intricacies of developing cultivated meat and reveals the key hurdles biotech scientists…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Commercial Readiness with ImmunityBio's Bobby Reddy, M.D.
56:54
56:54
Play later
Play later
Lists
Like
Liked
56:54
We love to hear from our listeners. Send us a message. This episode of the Business of Biotech begins with a personal story about my dad and the standard of care in bladder cancer, before shifting to the work that Dr. Bobby Reddy and his team at ImmunityBio are doing to change that standard of care. They're painfully close. Dr. Reddy, Chief Medical…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
44: Mastering the Art and Science of Glycan Engineering in Drug Development w/ Henning von Horsten - Part 2
18:26
18:26
Play later
Play later
Lists
Like
Liked
18:26
Does uncovering the secrets of glycan engineering feel like navigating a maze of molecular complexity? In this captivating continuation of our exploration into the world of glycan engineering, we delve deeper into groundbreaking innovations and the crucial role of analytics in ensuring consistent quality. Henning von Horsten, Professor of Industria…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
43: Mastering the Art and Science of Glycan Engineering in Drug Development w/ Henning von Horsten - Part 1
22:39
22:39
Play later
Play later
Lists
Like
Liked
22:39
Does unlocking the secrets of glycan engineering seem like navigating a labyrinth of molecular complexity? In this episode, we delve into the pivotal role of glycans as critical quality attributes (CQAs) in biotherapeutics. Henning von Horsten, Professor of Industrial Bioengineering at HTW Berlin (University of Applied Sciences in Berlin), sheds li…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Precision Drug Delivery with Ampersand Biomedicines' Jason Gardner, D.Phil.
49:47
49:47
Play later
Play later
Lists
Like
Liked
49:47
We love to hear from our listeners. Send us a message. Ampersand Biomedicines CEO Jason Gardner, D.Phil. first took the leap from a global pharmaceutical giant to a startup at the forefront of transplant medicine innovation. Since that time, he's seen most of the ups and the downs that come with biotech leadership, and in his latest venture with th…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
42: Revealing the Disciplined Pursuit of Less in Bioprocessing - Part 2
13:14
13:14
Play later
Play later
Lists
Like
Liked
13:14
Hey, fellow scientists! Do you find yourself buried under an avalanche of tasks, unsure which one truly matters? If you're tired of the chaos and want to reclaim control of your time and energy, stick around. Today, we're unlocking the secrets of Essentialism, tailor-made for busy biotech scientists like you. We discuss the importance of focusing o…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
41: Revealing the Disciplined Pursuit of Less in Bioprocessing - Part 1
15:02
15:02
Play later
Play later
Lists
Like
Liked
15:02
Hey, fellow scientists! Do you find yourself buried under an avalanche of tasks, unsure which one truly matters? If you're tired of the chaos and want to reclaim control of your time and energy, stick around. Today, we're unlocking the secrets of Essentialism, tailor-made for busy biotech scientists like you. We discuss the importance of focusing o…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Funding Alzheimer's Tx Dev with ADDF's Karen Harris
40:16
40:16
Play later
Play later
Lists
Like
Liked
40:16
We love to hear from our listeners. Send us a message. We've really been looking forward to dropping this episode with Karen Harris, Chief Financial Officer and Head of Mission-Related Investing at the Alzheimer's Drug Discovery Foundation. While the markets have warmed a bit since we recorded this episode, Karen's thoughtful perspective on the som…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
40: Balancing Perfusion Process Development and Sustainability w/ Jochen Sieck - Part 2
14:57
14:57
Play later
Play later
Lists
Like
Liked
14:57
Explore the intricate world of perfusion and its sustainability challenges in the part 2 of this episode. Dive into the operational side of managing vast quantities of media production and storage, and discover smart strategies to address these challenges. Jochen Sieck, Director of Cell Culture Media and Process Development at Merck Life Science, d…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
39: Balancing Perfusion Process Development and Sustainability w/ Jochen Sieck - Part 1
23:53
23:53
Play later
Play later
Lists
Like
Liked
23:53
Explore perfusion processes and sustainability with our guest, Jochen Sieck, Director of Cell Culture Media and Process Development at Merck Life Science. Learn about the evolution of perfusion methodologies, its historical roots in addressing product stability, and its recent return to continuous and integrated manufacturing. Jochen discusses the …
…
continue reading